Edition:
United Kingdom

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

8.75USD
6:49pm GMT
Change (% chg)

$-0.30 (-3.31%)
Prev Close
$9.05
Open
$9.40
Day's High
$9.43
Day's Low
$8.70
Volume
55,307
Avg. Vol
138,340
52-wk High
$29.35
52-wk Low
$8.07

Select another date:

Fri, Dec 8 2017

BRIEF-Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint

* COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM

BRIEF-Temasek Holdings (Private) Ltd ups share stake in Mastercard, Visa and Monsanto

* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares

BRIEF-Coherus Biosciences Q3 loss per share $1.09

* Coherus Biosciences reports third quarter 2017 operating and financial results

BRIEF-Coherus Biosciences files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​

* Coherus Biosciences Inc - Files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​ - SEC filing Source text: (http://bit.ly/2xYarNR) Further company coverage:

BRIEF-‍Temasek Holdings reports 11.32 pct passive stake in Coherus Biosciences

* ‍Temasek Holdings (private) Ltd​ reports 11.32 pct passive stake in Coherus Biosciences Inc as of Aug 24 - sec filing Source text - http://bit.ly/2esXsfi Further company coverage:

BRIEF-Coherus Biosciences announces positive topline results for study for Humira biosimilar vs European marketed Humira in healthy subjects

* Coherus Biosciences announces positive topline results for clinical pharmacokinetic bioequivalence study for CHS-1420 (Humira® biosimilar candidate) versus European marketed Humira in healthy subjects

BRIEF-Coherus secures private placement from Temasek

* Coherus Biosciences Inc - ‍Temasek plans to invest up to $150 million over two tranches​

BRIEF-Coherus Biosciences Q2 loss $1.08 per share

* Anticipate resubmitting BLA in U.S. At end of Q4 of 2017 for CHS-1701

BRIEF-Coherus Biosciences says completed restructuring plan to reduce operating costs

* Says commenced and completed, a restructuring plan to reduce operating costs and better align its workforce

BRIEF-Coherus Biosciences says projected filing timing for CHS-1420 biologics license application pushed to first half of 2018

* Coherus Biosciences - determined it is prudent to put into place alternative fill & finish vendor to support co's adalimumab biosimilar candidate chs-1420's bla filing

Select another date: